Search research articles
Contact Us
Filters
Showing results (61-70 of 72) with videos related to
Page
of 8
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 16, 1998
Radiation dosimetry for indium-111-pentetreotide
M G Stabin, P P Kooij, W H Bakker, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology
|
September 1, 1995
Biokinetics and dosimetry analysis in healthy volunteers for a two-injection (rest-stress) protocol of the myocardial perfusion imaging agent technetium 99m-labeled Q3
R C Rohe, S R Thomas, M G Stabin, et al.
Radiation Research
|
May 15, 2002
Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At
S J Kennel, S Mirzadeh, W C Eckelman, et al.
Health Physics
|
February 24, 2015
Development and validation of a GEANT4 radiation transport code for CT dosimetry
D E Carver, S D Kost, M J Fernald, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 1, 1989
Technetium-99m ECD: a new brain imaging agent: in vivo kinetics and biodistribution studies in normal human subjects
S Vallabhajosula, R E Zimmerman, M Picard, et al.
European Journal of Nuclear Medicine
|
August 7, 1999
Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC
M Cremonesi, M Ferrari, S Zoboli, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 27, 1998
Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy
N Iznaga-Escobar, L A Torres, A Morales, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 30, 1999
Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters
T M Behr, G Sgouros, M G Stabin, et al.
Cancer Research
|
June 11, 1999
High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model
T M Behr, M Béhé, M G Stabin, et al.
European Journal of Nuclear Medicine
|
June 1, 1997
Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases
W Y Lin, C P Lin, S J Yeh, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 72) with videos related to
Sort By:
Page
of 8
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 16, 1998
Radiation dosimetry for indium-111-pentetreotide
M G Stabin, P P Kooij, W H Bakker, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology
|
September 1, 1995
Biokinetics and dosimetry analysis in healthy volunteers for a two-injection (rest-stress) protocol of the myocardial perfusion imaging agent technetium 99m-labeled Q3
R C Rohe, S R Thomas, M G Stabin, et al.
Radiation Research
|
May 15, 2002
Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At
S J Kennel, S Mirzadeh, W C Eckelman, et al.
Health Physics
|
February 24, 2015
Development and validation of a GEANT4 radiation transport code for CT dosimetry
D E Carver, S D Kost, M J Fernald, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 1, 1989
Technetium-99m ECD: a new brain imaging agent: in vivo kinetics and biodistribution studies in normal human subjects
S Vallabhajosula, R E Zimmerman, M Picard, et al.
European Journal of Nuclear Medicine
|
August 7, 1999
Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC
M Cremonesi, M Ferrari, S Zoboli, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 27, 1998
Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy
N Iznaga-Escobar, L A Torres, A Morales, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 30, 1999
Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters
T M Behr, G Sgouros, M G Stabin, et al.
Cancer Research
|
June 11, 1999
High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model
T M Behr, M Béhé, M G Stabin, et al.
European Journal of Nuclear Medicine
|
June 1, 1997
Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases
W Y Lin, C P Lin, S J Yeh, et al.
Page
of 8